OBJECTIVE: To discuss the role and mechanism of ß4GalT1 both in vivo and in vitro glioma, observe whether pathophysiological processes of glioma can be improved after ß4GalT1 is knocked down, and study whether ß4GalT1 plays a role in malignant biological processes of glioma by regulating the apoptosis and immune processes. PATIENTS AND METHODS: Firstly, the distribution difference of ß4GalT1 in tumor tissues and normal tissues was analyzed by Gene Expression Profiling Interactive Analysis (GEPIA) tumor analysis system to deduce the possible role of ß4GalT1 in glioma. Secondly, whether the malignant degree of glioma was related to the expression of ß4GalT1 and its immunity using human tumor tissues and blood lymphocyte subsets was analyzed. Thirdly, interfere lentivirus vector with ß4GalT1 and knockdown ß4GalT1 was analyzed to observe whether the malignant degree of glioma has changed. Fourthly, interfere lentivirus vector with recombinant ß4GalT protein and ß4GalT1 was analyzed to verify the effect of ß4GalT in vitro test. Fifth, interfere lentivirus vector with recombinant ß4GalT protein and ß4GalT1 was analyzed to verify effect of ß4GalT in vivo test. Finally, we discuss whether ß4GalT is involved in the biological process of glioma through inflammatory reaction. RESULTS: In the GEPIA tumor analysis system, the expression in tumor was significantly higher than that in normal tissues. The expression of ß4GalT1 in glioma tissues was higher than that in normal tissues, and the higher the malignancy of the tumor, the higher the expression of ß4GalT1 in the glioma tissues, and the lower the immune level was. The expression of IDH1, MGMT, and ki-67 was reduced, and the survival rate of the mice with glioma was improved after ß4GalT1 was knocked down. In vitro tests, the activity of tumor cells and their reproductive ability can be reduced after ß4GalT1 was knocked down, the immune level of the body can be improved, and the level of tissue apoptosis can be reduced. After recombinant ß4GalT1 was given alone, the result was opposite to that of ß4GalT1 knocked down group. In vivo tests, gross tumor volume can be reduced after ß4GalT1 was knocked down, the immune level of the body can be improved, and the level of tissue apoptosis can be reduced. After recombinant ß4GalT1 was given alone, the result was opposite to that of ß4GalT1 knocked down group. After knocking down ß4GalT1, the expression of inflammatory factors can be reduced both in vivo and in vitro, and the inflammatory microenvironment of tumors can be improved. After recombinant ß4GalT1 was given alone, the result was opposite to that of ß4GalT1 knocked down group. CONCLUSIONS: The level of ß4GalT1 expression in tumor tissues was increased. The malignant degree of glioma is related to the expression of ß4GalT1 and its immunity. The level of tumor marker can be decreased, and the survival rate of glioma model mice can be increased after ß4GalT1 is knocked down. Apoptosis and immune injury caused by tumor can be improved and gross tumor volume can be deduced after ß4GalT1 is knocked down. During the development of glioma, ß4GalT1 may play a malignant biological role through inflammatory response.